Clinical Trials Logo
  1. Home
  2. RAS Mutation
  3. NCT04286360

Hematological Anomalies in Children With Rasopathy — RAS-HEMATO  

RAS Mutation Clinical Trial

Official title:
Hematological Anomalies in Children With Rasopathy

Clinical Trial Summary

During childhood, patients with RASopathies (Noonan syndrome and related diseases) can harbor various hematological anomalies ranging from isolated monocytosis, myelemia, thrombocytopenia or splenomegaly to myeloproliferative disorders. These anomalies may spontaneously disappear or persist, sometimes leading to juvenile myelomonocytic leukemia. Guidelines for initial screening and subsequent hematological follow-up have recently been published in France: peripheral blood analysis should be performed in all newly diagnosed patients and followed by biannual peripheral blood analysis in infants until the age of 2 years. In order to describe the characteristics of these abnormalities in terms of their incidence, age of occurrence, evolution and relation to genotype, we are conducting a longitudinal prospective study whose aim is to analyze peripheral blood cell counts and smears at diagnosis and one year later. In patients <3 years of age recruited at certain centers, biobanking of mononuclear cells will be performed. These data could yield a new insight into hematological anomalies in patients with RASopathies and thereby help physicians to determine the appropriate rhythm for hematological follow-up according to genotype.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04286360
Study type Observational
Source Assistance Publique - Hôpitaux de Paris
Contact Marion STRULLU, MD
Phone 187891611
Email marion.strullu@aphp.fr
Status Recruiting
Phase
Start date November 11, 2020
Completion date November 2029
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06229340 - Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations Phase 2
Recruiting NCT06206096 - PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC Phase 2
Recruiting NCT06287463 - Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway Phase 1/Phase 2
Active, not recruiting NCT05340621 - NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) Phase 1/Phase 2
Recruiting NCT05831995 - Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors. Phase 1
Recruiting NCT06321081 - ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC Phase 2
Recruiting NCT04395495 - RASopathy Biorepository
Not yet recruiting NCT04852250 - Centralized Tumour Board and Secondary Intervention Rate in mCRC
Recruiting NCT04985604 - Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors Phase 1/Phase 2
Recruiting NCT06218810 - Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer Phase 2
Active, not recruiting NCT04194359 - Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer Phase 2
Recruiting NCT06299839 - PAS-004 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04678648 - A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies Phase 1
Recruiting NCT04776655 - Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB Phase 3